Expert Physicians Discuss Guideline Focused Care in Hereditary Angioedema

Released On
May 6, 2021

Expires On
November 5, 2022

Media Type
Internet

Completion Time
60 minutes

Specialty
Allergy & Immunology, Dermatology, Emergency Medicine, Genetics

Topic(s)
Hereditary Angioedema

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine, US Hereditary Angioedema Association (HAEA), and RMEI Medical Education, LLC.

Funding provided by the US HAEA.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hours
  • Pharmacists — 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of clinicians involved in the diagnosis and management of patients with hereditary angioedema (HAE).

Statement of Need/Program Overview

This activity will provide learners with an opportunity to hear expert physicians discuss recently updated guidelines for HAE. The experts will cover important considerations in prophylactic treatment for HAE-C1INH, diagnosis and treatment for HAE-normal-C1INH, and how to create individualized HAE patient management plans.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize important considerations in prophylactic treatment for HAE-C1INH, including recent therapeutic advances and patient specific factors
  • Discuss the diagnostic and treatment approaches for patients with HAE-nl-C1INH
  • Develop individualized management plans, including logistics, education, and monitoring for HAE special patient populations

Faculty

FACULTY_NAME

Anthony J. Castaldo

President/CEO
US HAEA
Fairfax City, VA

FACULTY_NAME

Marc A. Riedl, MD, MS

Professor, Medicine
Clinical Director, US HAEA Angioedema Center
Clinical Service Chief and Training Program Director
Division of Rheumatology, Allergy & Immunology
University of California, San Diego
San Diego, CA

FACULTY_NAME

Aleena Banerji, MD

Clinical Director, Allergy and Clinical Immunology
Director, Drug Allergy Program
Associate Professor, Medicine
Division of Rheumatology, Allergy and Immunology
Harvard Medical School
Boston, MA

FACULTY_NAME

Sandra C. Christiansen, MD

Professor, Medicine
Department of Medicine
Division of Rheumatology, Allergy & Immunology
University of California, San Diego
San Diego, CA

FACULTY_NAME

William R. Lumry, MD

Clinical Professor, Internal Medicine
University of Texas Southwestern Medical School
Dallas, TX

FACULTY_NAME

Bruce L. Zuraw, MD

Professor, Medicine
Chair, Section of Allergy & Immunology
Director, Allergy & Immunology Training Program
University of California School of Medicine
San Diego, CA
Research Scientist, Veterans Medical Research Foundation
Director, Section of Allergy & Immunology
San Diego Veterans Affairs Medical Center
La Jolla, CA

Faculty Biographies

Click here to learn more about our presenters:
Faculty Bios

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, US HAEA, and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number -JA4008162-9999-21-2677-H01-P)

Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosures of Conflicts of Interest

The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Marc A. Riedl, MD, MS

  • Consulting: Adverum, Attune, BioCryst, Biomarin, CSL Behring, Ionis, Kalvista, Pfizer, Pharming, Pharvaris, RegenxBio, Shire/Takeda
  • Speaker’s Bureau: CSL Behring, Grifols, Pharming, Shire/Takeda
  • Research Investigator: BioCryst, CSL Behring, Ionis, Shire/Takeda

Aleena Banerji, MD

  • Consulting: BioCryst, Kalvista, Intellia, Pharvaris, Takeda
  • Contracted Research: BioCryst, Takeda

Sandra C. Christiansen, MD

  • Consulting: BioCryst, CSL Behring, Fresenius Kabi, Takeda
  • Speakers’ Bureau: GLG Consulting, Guidepoint

William R. Lumry, MD

  • Consulting: BioCryst, Biomarin, CSL Behring, Fresenius Kabi, Intellia, Kalvista, Pharming, Pharvaris, Shire/Takeda
  • Speakers’ Bureau: AstraZeneca, CSL Behring, Grifols, GSK, Pharming, Sanofi/Regeneron, Shire/Takeda
  • Research: ADMA, ALK, BioCryst, CSL Behring, Gossamer, Grifols, Ionis, Kalvista, Kedrion, Shire/Takeda, Therapure
  • Board Membership: US Hereditary Angioedema Association Medical Advisory Board

Bruce L. Zuraw, MD

  • Royalty: UpToDate
  • Receipt of Intellectual Property Rights/Patent Holder: TSKA
  • Advisory Boards: BioCryst, CSL Behring, Fresenius Kabi, Takeda

Planners and Managers

The Postgraduate Institute for Medicine planners and managers have nothing to disclose. The RMEI Medical Education, LLC planners and managers have nothing to disclose. The US HAEA planners and managers have nothing to disclose.

Instructions for Participation and Credit

There is no fee for this educational activity.

During the period May 6, 2021 through November 5, 2022, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the evaluation form. Select the desired certificate and click on Submit. Click on Download Certificate and print the certificate for your records.

Accreditation Support
Please contact Postgraduate Institute for Medicine Continuing Medical Education Department at inquiries@pimed.com or by calling 303-799-1930.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

HAEA Guidelines Deck

Click to view the following resources:
Hereditary Angioedema: Long-term Prophylaxis